ACM
CERE

AlphaCrest Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

AlphaCrest Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,328
Closed -$335K – 1445
2021
Q4 		$335K Buy
+10,328
New +$364K 0.01% 1233

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

AlphaCrest Capital Management's CERE Position: Q1 2022 in Review

AlphaCrest Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2022, closing a stake of 10,328 shares — an estimated $335K sold.

AlphaCrest Capital Management first reported a position in CERE in Q4 2021 and held it in 1 quarter. The position peaked at $335K in Q4 2021. 107 funds tracked by Wall St. Rank hold CERE as of Q1 2022.

  • AlphaCrest Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 10,328 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2022, an estimated $335K.
  • AlphaCrest Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • AlphaCrest Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $335K in Q4 2021.
  • 107 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2022.

Based on AlphaCrest Capital Management's 13F filing for Q1 2022, filed 12 May 2022.